Get the Stockscreener App
33.67
0.75%
0.25
After Hours:
33.67
Castle Biosciences Inc stock is traded at $33.67, with a volume of 199.99K.
It is up +0.75% in the last 24 hours and down -15.85% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
See More
Previous Close:
$33.42
Open:
$33.65
24h Volume:
199.99K
Relative Volume:
0.52
Market Cap:
$982.78M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-15.66
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
+4.11%
1M Performance:
-15.85%
6M Performance:
+63.76%
1Y Performance:
+26.01%
1-Day Range:
$33.40
$34.44
1-Week Range:
$31.39
$34.44
52-Week Range:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
33.67 | 975.48M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
513.56 | 188.45B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
208.56 | 145.88B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
634.90 | 50.00B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
126.94 | 35.04B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
327.53 | 31.53B | 3.17B | 642.63M | 539.81M | 10.77 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Can Castle Biosciences Inc. maintain its current growth rateRecession Risk & Precise Trade Entry Recommendations - mfd.ru
How do insiders feel about Castle Biosciences Inc2025 Market Outlook & Verified High Yield Trade Plans - baoquankhu1.vn
Aug Weekly: Why is CKPT stock going upJuly 2025 Action & Daily Entry Point Trade Alerts - baoquankhu1.vn
Castle Biosciences, Inc. (CSTL) Stock Analysis: A Promising 52% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Earnings Recap: Will Castle Biosciences Inc stock go up in YEAR2025 Big Picture & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Castle Biosciences (CSTL) loses 16.8% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Castle Biosciences stock jumps after FDA grants Breakthrough Device status to melanoma test - MSN
EV Market: Can Castle Biosciences Inc deliver alpha2025 Stock Rankings & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Aug Weekly: Can Castle Biosciences Inc. maintain its current growth rateEarnings Overview Report & Long-Term Investment Growth Plans - baoquankhu1.vn
Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
Castle Biosciences, Inc. $CSTL Shares Sold by Allianz Asset Management GmbH - MarketBeat
Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 49.91% Upside Potential for Investors - DirectorsTalk Interviews
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 3,200 Shares of Stock - MarketBeat
Derek Maetzold Sells 817 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
What Catalysts Are Rewriting The Castle Biosciences (CSTL) Story For Wall Street Analysts - Yahoo Finance
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - Finviz
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 - The Manila Times
Castle Biosciences to Release Fourth Quarter and Full-Year - GlobeNewswire
Castle Biosciences Enters Oversold Territory (CSTL) - Nasdaq
Castle Biosciences (NASDAQ:CSTL) Upgraded to "Strong-Buy" at Zacks Research - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Retail Trends: Should you avoid Castle Biosciences Inc stock right nowQuarterly Trade Report & Community Verified Watchlist Alerts - baoquankhu1.vn
The Analyst Verdict: Castle Biosciences In The Eyes Of 7 Experts - Benzinga
Are you looking for a top momentum pick? Why Castle Biosciences, Inc. (CSTL) is a great choice - MSN
Aug Outlook: How sensitive is Castle Biosciences Inc to inflationMarket Risk Report & Entry Point Strategy Guides - baoquankhu1.vn
AIGH Capital Management LLC Acquires New Position in Castle Biosciences, Inc. $CSTL - Defense World
Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice - Yahoo Finance
Castle Biosciences, Inc. (CSTL) Stock Analysis: A Healthcare Innovator with Strong Buy Ratings and 9.13% Upside Potential - DirectorsTalk Interviews
Castle Biosciences stock hits 52-week high at $42.25 By Investing.com - Investing.com Nigeria
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 4,017 Shares - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month HighWhat's Next? - MarketBeat
Castle Biosciences stock hits 52-week high at $42.25 - Investing.com
26,996 Shares in Castle Biosciences, Inc. $CSTL Acquired by Campbell & CO Investment Adviser LLC - MarketBeat
Risk Hedge: What are the future prospects of Castle Biosciences IncCPI Data & Daily Volume Surge Signals - baoquankhu1.vn
Insider Buy: What are the future prospects of Castle Biosciences IncQuarterly Market Review & Free Community Supported Trade Ideas - baoquankhu1.vn
Zacks.com Spotlights Perimeter Solutions, Interface, Castle Biosciences, and Great Lakes Dredge & Dock - Intellectia AI
Market Rankings: How sensitive is Castle Biosciences Inc to inflationJuly 2025 Weekly Recap & Daily Momentum Trading Reports - baoquankhu1.vn
Dividend Watch: How sensitive is Castle Biosciences Inc. to inflationAnalyst Downgrade & Weekly Return Optimization Plans - baoquankhu1.vn
Market Trends: Will Castle Biosciences Inc stock deliver better than expected guidance - Bộ Nội Vụ
Castle Biosciences (CSTL) Gets a Buy from Lake Street - The Globe and Mail
Castle Biosciences (CSTL) Sees PT Raised by Lake Street: Analyst Insights | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth - Yahoo Finance
The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook - Yahoo Finance
Castle Biosciences (CSTL) Expects 2025 Revenue to Surpass $340 M - GuruFocus
Castle Biosciences Expects 2025 Revenue to Exceed $340 Million - Intellectia AI
Castle Biosciences 2025 total revenue expected to exceed $340 million - marketscreener.com
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results - The Manila Times
Castle Biosciences 2025 Total Revenue Expected To Exceed $340 Million - TradingView — Track All Markets
San Gabriel Valley Tribune - FinancialContent
Castle Biosciences to buy Previse - MSN
Castle Biosciences, Inc. (CSTL) Stock Analysis: Riding the Wave of Healthcare Innovation with 9.68% Upside Potential - DirectorsTalk Interviews
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):